
NextCure NXTC
€ 8.56
-1.2%
Geschäftsbericht 2025
hinzugefügt 05.03.2026
NextCure Kurzfristige Verbindlichkeiten 2011-2026 | NXTC
Kurzfristige Verbindlichkeiten Jährlich NextCure
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.6 M | 9.57 M | 6.88 M | 9.13 M | 6.61 M | 10.3 M | 15 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 15 M | 6.61 M | 9.73 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Heron Therapeutics
HRTX
|
96.1 M | $ 0.79 | 1.9 % | $ 132 M | ||
|
Altimmune
ALT
|
15 M | $ 3.44 | 2.99 % | $ 303 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
5.75 M | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Incyte Corporation
INCY
|
1.52 B | $ 90.43 | -0.21 % | $ 17.7 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Inovio Pharmaceuticals
INO
|
42.6 M | $ 1.54 | -2.41 % | $ 34.1 M | ||
|
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
37.7 M | $ 13.57 | 7.1 % | $ 818 M | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
14 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
25.6 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
63 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | ||
|
KalVista Pharmaceuticals
KALV
|
45.2 M | $ 16.82 | -1.06 % | $ 835 M | ||
|
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
125 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Compugen Ltd.
CGEN
|
22.6 M | $ 2.13 | 1.67 % | $ 199 M | ||
|
Karyopharm Therapeutics
KPTI
|
92.3 M | $ 7.11 | -6.82 % | $ 866 K | ||
|
Denali Therapeutics
DNLI
|
102 M | $ 20.99 | 4.07 % | $ 3.45 B | ||
|
Keros Therapeutics
KROS
|
20.4 M | $ 11.16 | 1.82 % | $ 415 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.35 | 2.48 % | $ 722 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
6.27 M | - | -5.98 % | $ 34.1 M |